Di-Gesic, Doloxene to stay on market

The controversial painkillers Di-Gesic and Doloxene will remain on the market in Australia subject to heavy-duty prescribing restrictions, it has been confirmed.

The Therapeutic Goods Administration said Thursday it would not appeal the latest Administrative Appeals Tribunal ruling, meaning the restrictions effectively came into force on 10 October.

However, the new "prescriber confirmation form", which doctors will have to sign